Recruiting
Phase 1

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Sponsor:

Wugen, Inc.

Code:

NCT05674526

Conditions

Colorectal Cancer Metastatic

Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

WU-NK-101 - Dose Escalation

Cetuximab - Dose Escalation

WU-NK-101 - Cohort Expansion

Cetuximab - Cohort Expansion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-01. This information was provided to ClinicalTrials.gov by Wugen, Inc. on 2025-03-25.